Invasive Pneumococcal Disease in England and Wales: Vaccination Implications
Knowledge of the epidemiology of invasive pneumococcal disease (IPD) will aid in planning the use of pneumococcal vaccines. A United Kingdom (UK)—based surveillance in England and Wales (1995–1997) of 11,528 individuals with IPD and a local enhanced surveillance in the Oxford (UK) area (1995–1999) h...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 2001-01, Vol.183 (2), p.239-246 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 246 |
|---|---|
| container_issue | 2 |
| container_start_page | 239 |
| container_title | The Journal of infectious diseases |
| container_volume | 183 |
| creator | Sleeman, Karen Knox, Kyle George, Robert Miller, Elizabeth Waight, Pauline Griffiths, David Efstratiou, A. Broughton, K. Mayon-White, Richard T. Moxon, E. R. Crook, D. W. |
| description | Knowledge of the epidemiology of invasive pneumococcal disease (IPD) will aid in planning the use of pneumococcal vaccines. A United Kingdom (UK)—based surveillance in England and Wales (1995–1997) of 11,528 individuals with IPD and a local enhanced surveillance in the Oxford (UK) area (1995–1999) have been analyzed. IPD has a high attack rate in children, with 37.1–48.1 cases per 100,000 infants 65 years old per year, for England, Wales, and Oxford. The 7-valent conjugate vaccine includes serotypes causing ⩽79% of IPD in children 65 years old. The data also indicate that IPD varies by serotype, age, and country, emphasizing that the epidemiology of IPD is heterogeneous and requires continued surveillance. |
| doi_str_mv | 10.1086/317924 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_70578860</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30086935</jstor_id><oup_id>10.1086/317924</oup_id><sourcerecordid>30086935</sourcerecordid><originalsourceid>FETCH-LOGICAL-c449t-c7c7a3f85d7171e682a0fd299d71f1e857fd972bd21434cd0eb0a3b16905e4533</originalsourceid><addsrcrecordid>eNqF0Utv1DAQAGALgei2wD8ABSS4BWb8iGNuaNvSRSteKg9xsbyOg7wk9hInFfx7XLJqERLiYNnWfBp7Zgi5h_AUoa6eMZSK8htkgYLJsqqQ3SQLAEpLrJU6IIcpbQGAs0reJgeISEExWJD1KlyY5C9c8Ta4qY82Wmu64tgnZ5IrfChOwtfOhKa4XJ9M59Lz4qOx1gcz-hiKVb_rvP19TnfIrdZ0yd3d70fkw-nJ-fKsXL95uVq-WJeWczWWVlppWFuLRqJEV9XUQNtQpfK9RVcL2TZK0k1DkTNuG3AbMGyDlQLhuGDsiDyZ8-6G-H1yadS9T9Z1-Z8uTklLELKuK_gvxBqk4Ipn-OgvuI3TEHIRmlKmMP_zj2ftEFMaXKt3g-_N8FMj6Msp6HkKGT7YZ5s2vWuu2b7tGTzeA5Nyu9vBBOvTteMocrEqu4ezi9Pu34_dn802jXG4UgyyUUzkeDnHfRrdj6u4Gb7pSjIp9NnnL3r56jV_f758p0_ZL4p-ruE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223911713</pqid></control><display><type>article</type><title>Invasive Pneumococcal Disease in England and Wales: Vaccination Implications</title><source>Jstor Complete Legacy</source><source>MEDLINE</source><source>Oxford University Press Journals Current</source><source>Alma/SFX Local Collection</source><creator>Sleeman, Karen ; Knox, Kyle ; George, Robert ; Miller, Elizabeth ; Waight, Pauline ; Griffiths, David ; Efstratiou, A. ; Broughton, K. ; Mayon-White, Richard T. ; Moxon, E. R. ; Crook, D. W.</creator><creatorcontrib>Sleeman, Karen ; Knox, Kyle ; George, Robert ; Miller, Elizabeth ; Waight, Pauline ; Griffiths, David ; Efstratiou, A. ; Broughton, K. ; Mayon-White, Richard T. ; Moxon, E. R. ; Crook, D. W. ; Public Health Laboratory Service and the Oxford Pneumococcal Surveillance Group ; Public Health Laboratory Service ; Oxford Pneumococcal Surveillance Group ; on Behalf of the Public Health Laboratory Service and the Oxford Pneumococcal Surveillance Group</creatorcontrib><description>Knowledge of the epidemiology of invasive pneumococcal disease (IPD) will aid in planning the use of pneumococcal vaccines. A United Kingdom (UK)—based surveillance in England and Wales (1995–1997) of 11,528 individuals with IPD and a local enhanced surveillance in the Oxford (UK) area (1995–1999) have been analyzed. IPD has a high attack rate in children, with 37.1–48.1 cases per 100,000 infants <1 year old per year, and in older persons, with 21.2–36.2 cases per 100,000 persons >65 years old per year, for England, Wales, and Oxford. The 7-valent conjugate vaccine includes serotypes causing ⩽79% of IPD in children <5 years old, but only 66% in adults >65 years old. The data also indicate that IPD varies by serotype, age, and country, emphasizing that the epidemiology of IPD is heterogeneous and requires continued surveillance.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1086/317924</identifier><identifier>PMID: 11120930</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Adolescent ; Adult ; Age Distribution ; Aged ; Anti-Bacterial Agents - pharmacology ; Bacterial diseases ; Bacteriology ; Biological and medical sciences ; Child ; Child, Preschool ; Children ; Conjugate vaccines ; Drug Resistance, Microbial ; England - epidemiology ; Epidemiology ; Female ; Fundamental and applied biological sciences. Psychology ; Human bacterial diseases ; Humans ; Incidence ; Infant ; Infectious diseases ; Major Articles ; Male ; Medical sciences ; Microbial Sensitivity Tests ; Microbiology ; Middle Aged ; Parkinson disease ; Pneumococcal Infections - epidemiology ; Pneumococcal Infections - microbiology ; Pneumococcal Infections - prevention & control ; Pneumococcal meningitis ; Pneumococcal Vaccines - immunology ; Preventive medicine ; Serotyping ; Staphylococcal infections, streptococcal infections, pneumococcal infections ; Streptococcus pneumoniae ; Streptococcus pneumoniae - classification ; Streptococcus pneumoniae - isolation & purification ; Surveillance ; Vaccination ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Vaccines, Conjugate - immunology ; Wales - epidemiology</subject><ispartof>The Journal of infectious diseases, 2001-01, Vol.183 (2), p.239-246</ispartof><rights>Copyright 2001 Infectious Diseases Society of America</rights><rights>2001 by the Infectious Diseases Society of America 2001</rights><rights>2002 INIST-CNRS</rights><rights>Copyright University of Chicago, acting through its Press Jan 15, 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c449t-c7c7a3f85d7171e682a0fd299d71f1e857fd972bd21434cd0eb0a3b16905e4533</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30086935$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30086935$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14156909$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11120930$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sleeman, Karen</creatorcontrib><creatorcontrib>Knox, Kyle</creatorcontrib><creatorcontrib>George, Robert</creatorcontrib><creatorcontrib>Miller, Elizabeth</creatorcontrib><creatorcontrib>Waight, Pauline</creatorcontrib><creatorcontrib>Griffiths, David</creatorcontrib><creatorcontrib>Efstratiou, A.</creatorcontrib><creatorcontrib>Broughton, K.</creatorcontrib><creatorcontrib>Mayon-White, Richard T.</creatorcontrib><creatorcontrib>Moxon, E. R.</creatorcontrib><creatorcontrib>Crook, D. W.</creatorcontrib><creatorcontrib>Public Health Laboratory Service and the Oxford Pneumococcal Surveillance Group</creatorcontrib><creatorcontrib>Public Health Laboratory Service</creatorcontrib><creatorcontrib>Oxford Pneumococcal Surveillance Group</creatorcontrib><creatorcontrib>on Behalf of the Public Health Laboratory Service and the Oxford Pneumococcal Surveillance Group</creatorcontrib><title>Invasive Pneumococcal Disease in England and Wales: Vaccination Implications</title><title>The Journal of infectious diseases</title><addtitle>The Journal of Infectious Diseases</addtitle><addtitle>The Journal of Infectious Diseases</addtitle><description>Knowledge of the epidemiology of invasive pneumococcal disease (IPD) will aid in planning the use of pneumococcal vaccines. A United Kingdom (UK)—based surveillance in England and Wales (1995–1997) of 11,528 individuals with IPD and a local enhanced surveillance in the Oxford (UK) area (1995–1999) have been analyzed. IPD has a high attack rate in children, with 37.1–48.1 cases per 100,000 infants <1 year old per year, and in older persons, with 21.2–36.2 cases per 100,000 persons >65 years old per year, for England, Wales, and Oxford. The 7-valent conjugate vaccine includes serotypes causing ⩽79% of IPD in children <5 years old, but only 66% in adults >65 years old. The data also indicate that IPD varies by serotype, age, and country, emphasizing that the epidemiology of IPD is heterogeneous and requires continued surveillance.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Distribution</subject><subject>Aged</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Bacterial diseases</subject><subject>Bacteriology</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Conjugate vaccines</subject><subject>Drug Resistance, Microbial</subject><subject>England - epidemiology</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infant</subject><subject>Infectious diseases</subject><subject>Major Articles</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Parkinson disease</subject><subject>Pneumococcal Infections - epidemiology</subject><subject>Pneumococcal Infections - microbiology</subject><subject>Pneumococcal Infections - prevention & control</subject><subject>Pneumococcal meningitis</subject><subject>Pneumococcal Vaccines - immunology</subject><subject>Preventive medicine</subject><subject>Serotyping</subject><subject>Staphylococcal infections, streptococcal infections, pneumococcal infections</subject><subject>Streptococcus pneumoniae</subject><subject>Streptococcus pneumoniae - classification</subject><subject>Streptococcus pneumoniae - isolation & purification</subject><subject>Surveillance</subject><subject>Vaccination</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><subject>Vaccines, Conjugate - immunology</subject><subject>Wales - epidemiology</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0Utv1DAQAGALgei2wD8ABSS4BWb8iGNuaNvSRSteKg9xsbyOg7wk9hInFfx7XLJqERLiYNnWfBp7Zgi5h_AUoa6eMZSK8htkgYLJsqqQ3SQLAEpLrJU6IIcpbQGAs0reJgeISEExWJD1KlyY5C9c8Ta4qY82Wmu64tgnZ5IrfChOwtfOhKa4XJ9M59Lz4qOx1gcz-hiKVb_rvP19TnfIrdZ0yd3d70fkw-nJ-fKsXL95uVq-WJeWczWWVlppWFuLRqJEV9XUQNtQpfK9RVcL2TZK0k1DkTNuG3AbMGyDlQLhuGDsiDyZ8-6G-H1yadS9T9Z1-Z8uTklLELKuK_gvxBqk4Ipn-OgvuI3TEHIRmlKmMP_zj2ftEFMaXKt3g-_N8FMj6Msp6HkKGT7YZ5s2vWuu2b7tGTzeA5Nyu9vBBOvTteMocrEqu4ezi9Pu34_dn802jXG4UgyyUUzkeDnHfRrdj6u4Gb7pSjIp9NnnL3r56jV_f758p0_ZL4p-ruE</recordid><startdate>20010115</startdate><enddate>20010115</enddate><creator>Sleeman, Karen</creator><creator>Knox, Kyle</creator><creator>George, Robert</creator><creator>Miller, Elizabeth</creator><creator>Waight, Pauline</creator><creator>Griffiths, David</creator><creator>Efstratiou, A.</creator><creator>Broughton, K.</creator><creator>Mayon-White, Richard T.</creator><creator>Moxon, E. R.</creator><creator>Crook, D. W.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>20010115</creationdate><title>Invasive Pneumococcal Disease in England and Wales: Vaccination Implications</title><author>Sleeman, Karen ; Knox, Kyle ; George, Robert ; Miller, Elizabeth ; Waight, Pauline ; Griffiths, David ; Efstratiou, A. ; Broughton, K. ; Mayon-White, Richard T. ; Moxon, E. R. ; Crook, D. W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c449t-c7c7a3f85d7171e682a0fd299d71f1e857fd972bd21434cd0eb0a3b16905e4533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Distribution</topic><topic>Aged</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Bacterial diseases</topic><topic>Bacteriology</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Conjugate vaccines</topic><topic>Drug Resistance, Microbial</topic><topic>England - epidemiology</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infant</topic><topic>Infectious diseases</topic><topic>Major Articles</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Parkinson disease</topic><topic>Pneumococcal Infections - epidemiology</topic><topic>Pneumococcal Infections - microbiology</topic><topic>Pneumococcal Infections - prevention & control</topic><topic>Pneumococcal meningitis</topic><topic>Pneumococcal Vaccines - immunology</topic><topic>Preventive medicine</topic><topic>Serotyping</topic><topic>Staphylococcal infections, streptococcal infections, pneumococcal infections</topic><topic>Streptococcus pneumoniae</topic><topic>Streptococcus pneumoniae - classification</topic><topic>Streptococcus pneumoniae - isolation & purification</topic><topic>Surveillance</topic><topic>Vaccination</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><topic>Vaccines, Conjugate - immunology</topic><topic>Wales - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sleeman, Karen</creatorcontrib><creatorcontrib>Knox, Kyle</creatorcontrib><creatorcontrib>George, Robert</creatorcontrib><creatorcontrib>Miller, Elizabeth</creatorcontrib><creatorcontrib>Waight, Pauline</creatorcontrib><creatorcontrib>Griffiths, David</creatorcontrib><creatorcontrib>Efstratiou, A.</creatorcontrib><creatorcontrib>Broughton, K.</creatorcontrib><creatorcontrib>Mayon-White, Richard T.</creatorcontrib><creatorcontrib>Moxon, E. R.</creatorcontrib><creatorcontrib>Crook, D. W.</creatorcontrib><creatorcontrib>Public Health Laboratory Service and the Oxford Pneumococcal Surveillance Group</creatorcontrib><creatorcontrib>Public Health Laboratory Service</creatorcontrib><creatorcontrib>Oxford Pneumococcal Surveillance Group</creatorcontrib><creatorcontrib>on Behalf of the Public Health Laboratory Service and the Oxford Pneumococcal Surveillance Group</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sleeman, Karen</au><au>Knox, Kyle</au><au>George, Robert</au><au>Miller, Elizabeth</au><au>Waight, Pauline</au><au>Griffiths, David</au><au>Efstratiou, A.</au><au>Broughton, K.</au><au>Mayon-White, Richard T.</au><au>Moxon, E. R.</au><au>Crook, D. W.</au><aucorp>Public Health Laboratory Service and the Oxford Pneumococcal Surveillance Group</aucorp><aucorp>Public Health Laboratory Service</aucorp><aucorp>Oxford Pneumococcal Surveillance Group</aucorp><aucorp>on Behalf of the Public Health Laboratory Service and the Oxford Pneumococcal Surveillance Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Invasive Pneumococcal Disease in England and Wales: Vaccination Implications</atitle><jtitle>The Journal of infectious diseases</jtitle><stitle>The Journal of Infectious Diseases</stitle><addtitle>The Journal of Infectious Diseases</addtitle><date>2001-01-15</date><risdate>2001</risdate><volume>183</volume><issue>2</issue><spage>239</spage><epage>246</epage><pages>239-246</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>Knowledge of the epidemiology of invasive pneumococcal disease (IPD) will aid in planning the use of pneumococcal vaccines. A United Kingdom (UK)—based surveillance in England and Wales (1995–1997) of 11,528 individuals with IPD and a local enhanced surveillance in the Oxford (UK) area (1995–1999) have been analyzed. IPD has a high attack rate in children, with 37.1–48.1 cases per 100,000 infants <1 year old per year, and in older persons, with 21.2–36.2 cases per 100,000 persons >65 years old per year, for England, Wales, and Oxford. The 7-valent conjugate vaccine includes serotypes causing ⩽79% of IPD in children <5 years old, but only 66% in adults >65 years old. The data also indicate that IPD varies by serotype, age, and country, emphasizing that the epidemiology of IPD is heterogeneous and requires continued surveillance.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>11120930</pmid><doi>10.1086/317924</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 2001-01, Vol.183 (2), p.239-246 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70578860 |
| source | Jstor Complete Legacy; MEDLINE; Oxford University Press Journals Current; Alma/SFX Local Collection |
| subjects | Adolescent Adult Age Distribution Aged Anti-Bacterial Agents - pharmacology Bacterial diseases Bacteriology Biological and medical sciences Child Child, Preschool Children Conjugate vaccines Drug Resistance, Microbial England - epidemiology Epidemiology Female Fundamental and applied biological sciences. Psychology Human bacterial diseases Humans Incidence Infant Infectious diseases Major Articles Male Medical sciences Microbial Sensitivity Tests Microbiology Middle Aged Parkinson disease Pneumococcal Infections - epidemiology Pneumococcal Infections - microbiology Pneumococcal Infections - prevention & control Pneumococcal meningitis Pneumococcal Vaccines - immunology Preventive medicine Serotyping Staphylococcal infections, streptococcal infections, pneumococcal infections Streptococcus pneumoniae Streptococcus pneumoniae - classification Streptococcus pneumoniae - isolation & purification Surveillance Vaccination Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Vaccines, Conjugate - immunology Wales - epidemiology |
| title | Invasive Pneumococcal Disease in England and Wales: Vaccination Implications |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T13%3A33%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Invasive%20Pneumococcal%20Disease%20in%20England%20and%20Wales:%20Vaccination%20Implications&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Sleeman,%20Karen&rft.aucorp=Public%20Health%20Laboratory%20Service%20and%20the%20Oxford%20Pneumococcal%20Surveillance%20Group&rft.date=2001-01-15&rft.volume=183&rft.issue=2&rft.spage=239&rft.epage=246&rft.pages=239-246&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1086/317924&rft_dat=%3Cjstor_proqu%3E30086935%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223911713&rft_id=info:pmid/11120930&rft_jstor_id=30086935&rft_oup_id=10.1086/317924&rfr_iscdi=true |